Patent №
US 7,892,829
Granted
2011-02-22
Filed 2009
Owner
OSIRIS THERAPEUTICS, INC.
+1 more
Lab
—
AI components
1
planning
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
12395949
Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
AI classification
Ownership
OSIRIS THERAPEUTICS, INC.
assignment · 241650865
MESOBLAST INTERNATIONAL SÀRL
assignment · 315330828
Assignors
PITTENGER, MARK F., GORDON, STEPHEN L., MACKAY, ALASTAIR MORGAN, MARTIN, BRADLEY J.
On an employer assignment, the assignors are typically the inventors.